To review, develop and recommend the standards, limits and conditions under which a registrant may administer a drug or substance to patients and to maintain patient safety and public protection with respect to authorized pharmacist’s administration of injections to patients or administration of drugs by intranasal route to patients.
Wilson Tsui (Chair)
Bing Wang (Vice-Chair)
Doreen Leong (staff resource)
Alex Dar Santos
Wendy Woodfield (effective May 1, 2020)
Number of Meetings: 3 videoconferences
Accomplishments of the Year
Provided the Board an update on the status of Drug Administration Committee’s (DAC) recommendations made to them at its February 15, 2019, to remove the restrictions on drug administration by injection and intranasal route (June 12, 2020).
- Received an update on the work of the Safe Drug Administration by Pharmacists Working Group (May 25, 2020).
- Recommended proposed amendments to the Drug Administration by Injection and Intranasal Route Standards, Limits and Conditions to the Board (September 18, 2020).
Goals for Next Fiscal Year
- To remove the restrictions on the Drug Administration by Injection and Intranasal Route Standards, Limits and Conditions.
- Have the “Drug Administration by Pharmacists” Report presented to the Ministry of Health (March 9, 2021).